Efficacy and Toxicity of Factor Xa Inhibitors
Authors:
Open Access
- 15 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 16 (1) , 74-88
Abstract
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for cardiovascular event prevention in patients with acute coronary syndrome. These antithrombotic agents directly and selectively inhibit factor Xa, and do not require coagulation monitoring and dose adjustment. Several of these drugs have shown promising results and have the potential to either replace or act as alternatives to traditional anticoagulants (heparins, vitamin K antagonists). This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.Keywords
This publication has 21 references indexed in Scilit:
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial FibrillationJACC, 2012
- Les nouveaux anticoagulants dans la maladie thrombo-embolique veineuseRevue des Maladies Respiratoires, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban with Antiplatelet Therapy after Acute Coronary SyndromeNew England Journal of Medicine, 2011
- Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolismEuropean Heart Journal, 2011
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)American Heart Journal, 2010
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialThe Lancet, 2009
- A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Thrombosis and Haemostasis, 2009
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging studyJournal of Thrombosis and Haemostasis, 2008